FundedIQ
Biotechnology

NicOx: Funding, Investors & Team (Sep 2026)

NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for inflammation and cardio-metabolic diseases. Their product candidates include Naproxcinod for osteoarthritis and NCX 6560 for cardiovascular diseases. They also have products in clinical trials for glaucoma, respiratory disorders, allergic rhinitis, and hypertension. NicOx is working on developing treatments for skin disorders and diabetic retinopathy, among other conditions. The company has partnerships with various organizations for research and development. Founded in 1996, NicOx is based in Sophia Antipolis, France.

www.nicox.com LinkedIn Valbonne, France 51-100 employees
Total raised
$25.5M
Rounds
4
Latest
Undisclosed round
Jun 2026

NicOx has raised $25.5M across 4 funding rounds on record, the most recent an undisclosed round of $6.9M announced in Jun 2026.

That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

NicOx Company Profile and Key Stats

Total funding raised
$25.5M
across 4 rounds on record
Funding rounds on record
4
Latest funding round
Undisclosed round
$6.9M in Jun 2026
Employees
51-100
reported band
Headquarters
Valbonne, France

Latest funding round on record: Jun 2026.

NicOx Funding Rounds

Date
Round
Amount
Undisclosed round
$6.9M
Undisclosed round
$4.7M
Undisclosed round
$3.6M
Undisclosed round
$10.3M

NicOx raised $10.3M in an undisclosed round announced in Nov 2022.

1.7 years later, an undisclosed round of $3.6M was announced in Jul 2024.

1.5 years later, an undisclosed round of $4.7M was announced in Jan 2026.

5 months later, an undisclosed round of $6.9M was announced in Jun 2026.

NicOx Founders and Leadership Team

Name
Role
Contact
Gavin Spencer
Founder
Locked
Michele Garufi
Founder
Locked

Contact details for the NicOx team: 2 of 2 have an email address on file.

Start 14-day free trial →

NicOx Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,179
$8.0M
1,705
$6.7M

NicOx's latest round of $6.9M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like NicOx in Biotechnology and Valbonne

Companies Similar to NicOx

Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…

Series A $12.6M

TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…

Series D $34.0M

Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…

Undisclosed round $1.7M

One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…

Undisclosed round

Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…

Undisclosed round $120M

NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…

Undisclosed round $8.4M

AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…

Undisclosed round $11.6M

Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…

Undisclosed round $116M

Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…

Undisclosed round $7.0M

Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…

Undisclosed round $45.0M

AB Science was established in 2001 by a group of individuals in the medical and business fields who are…

Undisclosed round $3.7M

Kahimmune Therapeutics is a cutting-edge biotech startup that is repurposing the cancer immunopeptidome to…

Undisclosed round $120k

NicOx Funding FAQs

What does NicOx do?

NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for inflammation and cardio-metabolic diseases. Their product candidates include Naproxcinod for osteoarthritis and NCX 6560 for cardiovascular diseases. They also have products in clinical trials for glaucoma, respiratory disorders, allergic rhinitis, and hypertension. NicOx is working on developing treatments for skin disorders and diabetic retinopathy, among other conditions. The company has partnerships with various organizations for research and development. Founded in 1996, NicOx is based in Sophia Antipolis, France.

How much funding has NicOx raised?

NicOx has raised $25.5M across 4 rounds on record. The most recent is an undisclosed round of $6.9M announced in Jun 2026.

When did NicOx last raise funding?

NicOx's most recent funding round on record is an undisclosed round of $6.9M, announced in Jun 2026.

Who founded NicOx?

FundedIQ lists Gavin Spencer (Founder), Michele Garufi (Founder) at NicOx.

Where is NicOx headquartered?

NicOx is based in Valbonne, Provence-Alpes-Cote D'azur, France.

How many employees does NicOx have?

NicOx is in the 51-100 employee band.

How does NicOx's funding compare to other Biotechnology startups?

NicOx's latest round of $6.9M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.

About FundedIQ's NicOx Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for NicOx is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.